in Existing Drugs
they’re not getting into clinical trials for the
diseases where they can do the most good.
We’re here to change that.
PCUT BioPartners acquires medically promising drug programs
that other companies have deprioritized. Our venture partnerships
allow us to clinically develop them at much lower cost.
Every existing drug with potential efficacy in diseases
with unmet medical need is a breakthrough opportunity.
The venture platform matches these with
cheap options for investors.
PCUT BioPartners is a commercial developer of early clinical stage drugs. The company licenses in products that have solid medical rationale for efficacy in any of the deadly diseases for which there is no meaningfully effective approved treatment. PCUT BioPartners is a “Venture-Biotech” structure that forms a product development team around each asset, funds the program, and spins off the LLC as a product-specific partnership (PSP). The value prospect is a reduction in front-end costs to enable greater therapy development for patients in need.